Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mitoxantrone (novantrone): a review of experimental and early clinical studies.

× No keyword cloud information.

30 in total

Review 1. Immunosuppressive agents in multiple sclerosis.

Authors: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal: Neurotherapeutics Date: 2007-10 Impact factor: 7.620

2. Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

Authors: Boren Lin; Dylan Launder; Destiny Y Bailey; Frank K Assifuah; Olivia A Miller; Heather R Conti; Jianyang Du; Boyd M Koffman
Journal: Mult Scler Relat Disord Date: 2020-05-16 Impact factor: 4.339

Review 3. Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors: J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal: Pharm Weekbl Sci Date: 1988-12-09

4. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.

Authors: S D Williams; R Birch; E Velez-Garcia; R Gams
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850

5. A phase II study of mitozantrone in advanced carcinoma of the ovary.

Authors: R Coleman; J Clarke; M Gore; E Wiltshaw; M Slevin; P Harper
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

6. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.

Authors: H T Mouridsen; M Cornbleet; R Stuart-Harris; I Smith; R Coleman; R Rubens; M McDonald; H Rainer; A van Oosterom; J Smyth
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850

7. Mitoxantrone as a first-line treatment of advanced breast cancer.

Authors: K Landys; S Borgstrom; T Andersson; H Noppa
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850

8. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group).

Authors: H B Muss; B N Bundy; H D Homesley; G Wilbanks
Journal: Invest New Drugs Date: 1987 Impact factor: 3.850

9. Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.

Authors: J H Schiller; B Storer; R Arzoomanian; K Tutsch; D Alberti; D Spriggs
Journal: Invest New Drugs Date: 1993-11 Impact factor: 3.850

10. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Authors: R T Dorr; D S Alberts; M Soble
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333